[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100314599":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":23,"locations":29,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":10,"eligibilityCriteria":54,"healthyVolunteers":51,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":73,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Medical College of Wisconsin","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Participants who received CAR-T cells.",null,"Participants who received CAR-T cells at Froedtert Hospital \\& the Medical College of Wisconsin in clinical trials (e.g., NCT05976555, NCT05094206, NCT05990465, NCT03019055 or NCT04186520).",[13],"Other: Long-Term Follow-Up of Participants who Received CAR-T cells",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Long-Term Follow-Up of Participants who Received CAR-T cells","No study drug is administered in this study. Participants who received CAR-T cells in a previous trial will be evaluated in this trial for long-term safety and efficacy.",[9],[20],{"name":21,"affiliation":5,"role":22},"Nirav Shah","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Medical College of Wisconsin Clinical Cancer Center","CONTACT","414-805-8900","cccto@mcw.edu",[30],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Froedtert Hospital & Medical College of Wisconsin","RECRUITING","Milwaukee","Wisconsin","53226","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-87.90647,43.0389,{"lat":42,"lon":41},[45],{"name":46,"role":26,"phone":27,"phoneExt":10,"email":28},"Cancer Center Clinical Trials Office",{"type":22,"investigatorFullName":21,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Associate Professor","100314599","long-term-follow-up-study-of-patients-receiving-car-t-cells-100314599",false,"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-T Cells","Inclusion Criteria:\n\n* All participants who enrolled in a CAR-T study at Froedtert Hospital \\& the Medical College of Wisconsin.\n\nExclusion Criteria:\n\n* There are no exclusion criteria for this study.","ALL","18 Years","80 Years",{"count":59,"type":60},500,"ESTIMATED","OBSERVATIONAL","This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin\u002F Froedtert Hospital. The clinical trials include the following:\n\nPhase 1 Study of CAR-20\u002F19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055); Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma (NCT05976555); CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206); LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies (NCT05990465); CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (NCT04186520)",[64,65,66,67,68,69,70,71,72],"Chronic Lymphocytic Leukemia","Lymphomas Non-Hodgkin's B-Cell","Lymphoma, Small Lymphocytic","Mantle Cell Lymphoma","Central Nervous System Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Burkitt Lymphoma","Multiple Myeloma",[74,75],"CAR-T Cell Therapy","chimeric antigen receptor","2025-11-06",{"date":78,"type":79},"2025-11-10","ACTUAL",{"date":81,"type":79},"2017-12-01",{"date":83,"type":60},"2035-01-01",{"name":5,"class":6},1]